| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.0071 | 0.9 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | selumetinib:piperlongumine (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | AA-COCF3 | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | Pazopanib | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | BMS-509744 | GDSC1000 | pan-cancer | AAC | -0.0067 | 0.9 |